202 related articles for article (PubMed ID: 38214723)
1. [The application of real-world evidence in drug regulatory decision-making].
Wicherski J; Haenisch B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
[TBL] [Abstract][Full Text] [Related]
2. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
[TBL] [Abstract][Full Text] [Related]
3. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
[TBL] [Abstract][Full Text] [Related]
4. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
6. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
Li P; Wang S; Chen Y
Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
[TBL] [Abstract][Full Text] [Related]
7. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
8. The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making.
Baumfeld Andre E; Carrington N; Siami FS; Hiatt JC; McWilliams C; Hiller C; Surinach A; Zamorano A; Pashos CL; Schulz WL
Clin Pharmacol Ther; 2022 Dec; 112(6):1172-1182. PubMed ID: 35213741
[TBL] [Abstract][Full Text] [Related]
9. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
10. Real-world evidence to support regulatory decision making: New or expanded medical product indications.
Franklin JM; Liaw KL; Iyasu S; Critchlow CW; Dreyer NA
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):685-693. PubMed ID: 33675248
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
[TBL] [Abstract][Full Text] [Related]
12. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
[TBL] [Abstract][Full Text] [Related]
13. Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.
McNair D; Lumpkin M; Kern S; Hartman D
Clin Pharmacol Ther; 2022 Jan; 111(1):44-51. PubMed ID: 34655224
[TBL] [Abstract][Full Text] [Related]
14. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
15. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
[TBL] [Abstract][Full Text] [Related]
16. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
[TBL] [Abstract][Full Text] [Related]
17. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Hiramatsu K; Barrett A; Miyata Y;
Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
[TBL] [Abstract][Full Text] [Related]
18. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
[TBL] [Abstract][Full Text] [Related]
19. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.
Burns L; Roux NL; Kalesnik-Orszulak R; Christian J; Hukkelhoven M; Rockhold F; O'Donnell J
Clin Ther; 2022 Mar; 44(3):420-437. PubMed ID: 35181179
[TBL] [Abstract][Full Text] [Related]
20. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
